NASDAQ:AKYA - Akoya Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.33
  • Forecasted Upside: 27.11 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$12.85
▲ +0.03 (0.23%)

This chart shows the closing price for AKYA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Akoya Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AKYA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AKYA

Analyst Price Target is $16.33
▲ +27.11% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Akoya Biosciences in the last 3 months. The average price target is $16.33, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 27.11% upside from the last price of $12.85.

This chart shows the closing price for AKYA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Akoya Biosciences.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/22/2022BTIG ResearchInitiated CoverageBuy$16.00Low
5/15/2022Piper SandlerLower Price TargetNA$18.00 ➝ $14.00High
3/17/2022Piper SandlerLower Price TargetOverweight$23.00 ➝ $18.00Low
3/15/2022Morgan StanleyLower Price TargetOverweight$20.00 ➝ $19.00High
2/15/2022Morgan StanleyLower Price TargetOverweight$24.00 ➝ $20.00Low
5/11/2021JPMorgan Chase & Co.Initiated CoverageOverweight$23.00High
5/11/2021Piper SandlerInitiated CoverageOverweight$28.00High
5/11/2021Morgan StanleyInitiated CoverageOverweight$26.00High
(Data available from 6/30/2017 forward)

News Sentiment Rating

0.60 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
12/2/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/1/2022
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/31/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/2/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/1/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/31/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2022

Current Sentiment

  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Akoya Biosciences logo
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Read More

Today's Range

Now: $12.85
Low: $12.07
High: $12.98

50 Day Range

MA: $10.26
Low: $8.38
High: $12.85

52 Week Range

Now: $12.85
Low: $8.02
High: $21.84

Volume

52,900 shs

Average Volume

77,009 shs

Market Capitalization

$483.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.3

Frequently Asked Questions

What sell-side analysts currently cover shares of Akoya Biosciences?

The following Wall Street sell-side analysts have issued research reports on Akoya Biosciences in the last year: BTIG Research, Morgan Stanley, and Piper Sandler.
View the latest analyst ratings for AKYA.

What is the current price target for Akoya Biosciences?

0 Wall Street analysts have set twelve-month price targets for Akoya Biosciences in the last year. Their average twelve-month price target is $16.33, suggesting a possible upside of 27.1%.
View the latest price targets for AKYA.

What is the current consensus analyst rating for Akoya Biosciences?

Akoya Biosciences currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AKYA will outperform the market and that investors should add to their positions of Akoya Biosciences.
View the latest ratings for AKYA.

How do I contact Akoya Biosciences' investor relations team?

The company's listed phone number is 855-896-8401 and its investor relations email address is [email protected] The official website for Akoya Biosciences is www.akoyabio.com. Learn More about contacing Akoya Biosciences investor relations.